08:26 AM EDT, 07/31/2025 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) reported Q2 non-GAAP net income Thursday of $0.32 per diluted share, down from $0.56 a year earlier.

Analysts polled by FactSet expected $0.02.

Revenue for the quarter ended June 30 was $773.7 million, up from $659.8 million a year earlier.

Analysts surveyed by FactSet expected $654.5 million.

The company's shares were up 7.2% in recent Thursday premarket activity.